Read by QxMD icon Read

Journal of Clinical Lipidology

Sam Mirzaee, James D Cameron
No abstract text is available yet for this article.
October 9, 2018: Journal of Clinical Lipidology
Leopoldo Pérez de Isla, Rodrigo Alonso, Pedro Mata
No abstract text is available yet for this article.
October 9, 2018: Journal of Clinical Lipidology
Jun Tang, Yinkun Yan, Jie Li, Bo Yang, Xiaoyuan Zhao, Yi Wan, Ju-Sheng Zheng, Jie Mi, Duo Li
BACKGROUND: Observational studies have reported inconsistent results on the association between circulating fatty acids and obesity. OBJECTIVE: The objective of this study was to investigate the relationship between erythrocyte phospholipid fatty acid composition and obesity in children and adolescents. METHODS: We conducted a case-control study including 1442 obese and 1442 normal-weight children and adolescents. Circulating fatty acid composition between cases and controls were compared both in the present study and literature-based meta-analysis...
September 25, 2018: Journal of Clinical Lipidology
Maximilian Tscharre, Robert Herman, Miklos Rohla, Edita Piackova, Kris G Vargas, Serdar Farhan, Matthias K Freynhofer, Thomas W Weiss, Kurt Huber
BACKGROUND: Patients with familial hypercholesterolemia (FH) are at increased risk for premature and subsequent cardiovascular disease. Data on long-term major adverse cardiovascular events (MACE) in patients with FH after percutaneous coronary intervention (PCI) in the era of high-intensity statins are scarce. OBJECTIVE: We assessed the prognostic impact of clinically diagnosed FH on long-term MACE, a composite of all-cause death, myocardial infarction, and ischemic stroke in patients admitted for stable coronary artery disease (SCAD) or acute coronary syndromes (ACSs) undergoing PCI...
September 22, 2018: Journal of Clinical Lipidology
Micah L Olson, Ana Rentería-Mexía, Margery A Connelly, Sonia Vega-López, Erica G Soltero, Yolanda P Konopken, Allison N Williams, Felipe G Castro, Colleen S Keller, Hongwei P Yang, Michael W Todd, Gabriel Q Shaibi
BACKGROUND: Obese youth with prediabetes are at increased risk for premature morbidity and mortality through multiple mechanisms, including increased systemic inflammation. GlycA is a novel measure of systemic inflammation that predicts type II diabetes, cardiovascular events, and all-cause mortality in adults. OBJECTIVE: The purpose of the present study was to examine changes in GlycA after lifestyle intervention among obese, prediabetic Latino youth. METHODS: Obese, prediabetic Latino youth (n = 27; 15...
September 22, 2018: Journal of Clinical Lipidology
François Moreau, Claire Blanchard, Christophe Perret, Laurent Flet, Frédéric Douane, Eric Frampas, Eric Mirallie, Mikael Croyal, Audrey Aguesse, Michel Krempf, Xavier Prieur, Matthieu Pichelin, Bertrand Cariou, Cédric Le May
BACKGROUND: Beyond the hepatobiliary pathway, studies have demonstrated that direct transintestinal cholesterol efflux (TICE) of plasma-derived cholesterol may contribute to reverse cholesterol transport. The clinical evidence of TICE in human remains challenged because of the difficulty to discriminate the hepatobiliary and transintestinal routes in vivo. OBJECTIVE: To provide the first proof of concept that TICE exists in vivo in humans by demonstrating that plasma labeled cholesterol can be excreted in the feces of patients with complete bile duct obstruction...
September 21, 2018: Journal of Clinical Lipidology
Toshio Murase, Akira Takeshita, Sadao Arimoto
In this case study, we followed the thyroid function and serum lipid levels of a patient with painless thyroiditis. Serum lipid levels were decreased during the hyperthyroid phase and elevated during the hypothyroid phase. Both serum lipid levels and thyroid function returned to normative values following a course of thyroid replacement treatment.
September 21, 2018: Journal of Clinical Lipidology
Vadzim Chyzhyk, Sarah Kozmic, Alan S Brown, Lisa C Hudgins, Thomas J Starc, Ashley Deleigh Davila, Thomas C Blevins, Margaret R Diffenderfer, Lihong He, Andrew S Geller, Caitlin Rush, Robert A Hegele, Ernst J Schaefer
BACKGROUND: Triglyceride (TG) concentrations >2000 mg/dL are extremely elevated and increase the risk of pancreatitis. OBJECTIVES: We characterized five cases and two kindreds and ascertained prevalence in a reference laboratory population. METHODS: Plasma lipids and DNA sequences of LPL, GPIHBP1, APOA5, APOC2, and LMF1 were determined in cases and two kindreds. Hypertriglyceridemia prevalence was assessed in 440,240 subjects. RESULTS: Case 1 (female, age 28 years) had TG concentrations >2000 mg/dL and pancreatitis since infancy...
September 18, 2018: Journal of Clinical Lipidology
Martine Paquette, Sophie Bernard, Isabelle Ruel, David W Blank, Jacques Genest, Alexis Baass
BACKGROUND: Familial hypercholesterolemia (FH) is the most common genetic disorder of lipoprotein metabolism, affecting 1:250 individuals worldwide. This monogenic disease is associated with lifelong elevation in circulating low-density lipoprotein cholesterol and premature cardiovascular disease (CVD). In 2016, the estimated prevalence of diabetes in Canada was 9%. In the FH population, little is known about the prevalence of diabetes and its impact on CVD risk. OBJECTIVE: The objectives of this study were to investigate the prevalence of diabetes among a large cohort of FH patients and to investigate the association between diabetes and CVD risk...
September 17, 2018: Journal of Clinical Lipidology
Allan D Sniderman, Jacqueline de Graaf, George Thanassoulis, André J Tremblay, Seth S Martin, Patrick Couture
BACKGROUND: Type III hyperlipoproteinemia is a highly atherogenic dyslipoproteinemia characterized by hypercholesterolemia and hypertriglyceridemia due to markedly increased numbers of cholesterol-enriched chylomicron and very-low-density lipoprotein (VLDL) remnant lipoprotein particles. Type III can be distinguished from mixed hyperlipidemia based on a simple diagnostic algorithm, which involves total cholesterol, triglycerides, and apolipoprotein B (apoB). However, apoB is not measured routinely...
September 14, 2018: Journal of Clinical Lipidology
Michael B Boffa, Saverio Stranges, Neil Klar, Patrick M Moriarty, Gerald F Watts, Marlys L Koschinsky
Elevated plasma concentrations of lipoprotein(a) [Lp(a)] are an independent, and possibly causal, risk factor for atherothrombotic diseases including coronary heart disease. The principal evidence base for this comes from large population studies focusing on first atherothrombotic events. However, inconsistent findings have been reported from studies investigating the impact of elevated Lp(a) on atherothrombotic events in subjects with preexisting cardiovascular disease. This question is very important because the secondary prevention population is recommended for Lp(a) screening by some guidelines and could be an important target group for Lp(a)-lowering therapies that are currently on the horizon...
September 11, 2018: Journal of Clinical Lipidology
Jesús M Martín-Campos, Núria Plana, Rosaura Figueras, Daiana Ibarretxe, Assumpta Caixàs, Eduardo Esteve, Antonio Pérez, Marta Bueno, Marta Mauri, Rosa Roig, Susana Martínez, Xavier Pintó, Luís Masana, Josep Julve, Francisco Blanco-Vaca
BACKGROUND: Autosomal dominant hypercholesterolemia (ADH) is associated with mutations in the low-density lipoprotein (LDL) receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin 9 (PCSK9) genes, and it is estimated to be greatly underdiagnosed. The most cost-effective strategy for increasing ADH diagnosis is a cascade screening from mutation-positive probands. OBJECTIVE: The objective of this study was to evaluate the results from 2008 to 2016 of ADH genetic analysis performed in our clinical laboratory, serving most lipid units of Catalonia, a Spanish region with approximately 7...
September 7, 2018: Journal of Clinical Lipidology
Chau L B Ho, Enayet K Chowdhury, Monique Breslin, Jenny Doust, Christopher M Reid, Lindon M H Wing, Mark R Nelson
BACKGROUND: There is currently insufficient evidence to support the use of lipid-lowering drug treatment (LLT) for primary prevention of cardiovascular disease (CVD) in the elderly. OBJECTIVES: We examined the relationship of early initiation of LLT with short- and long-term all-cause and CVD mortality in persons older than 65 years in this post hoc study from the Second Australian National Blood Pressure study (ANBP2). METHODS: This was an in- and post-trial observational study...
September 6, 2018: Journal of Clinical Lipidology
Petra El Khoury, Philippe Couvert, Sandy Elbitar, Youmna Ghaleb, Yara Abou-Khalil, Yara Azar, Carine Ayoub, Alexandre Superville, Maryse Guérin, Jean-Pierre Rabès, Mathilde Varret, Catherine Boileau, Selim Jambart, Philippe Giral, Alain Carrié, Wilfried Le Goff, Marianne Abifadel
BACKGROUND: The Middle East region is characterized by low levels of high-density lipoprotein cholesterol (HDL-C). To date, no genetic study has investigated the cause of low HDL-C in the Lebanese population. OBJECTIVE: Our objective was to study the genetic causes for hypoalphalipoproteinemia in a Lebanese family with extremely low HDL-C levels. METHODS: We sequenced the ABCA1 gene and evaluated cholesterol efflux, inflammatory, and metabolic profiles in the proband and his family...
September 1, 2018: Journal of Clinical Lipidology
G Kees Hovingh, John R Guyton, Gisle Langslet, Robert Dufour, Marie T Baccara-Dinet, Chantal Din-Bell, Garen Manvelian, Michel Farnier
BACKGROUND: ODYSSEY OLE (NCT01954394) was an open-label extension (OLE) study for patients with heterozygous familial hypercholesterolemia (HeFH) who had completed previous phase 3 clinical trials with alirocumab. Alirocumab dose could be increased or decreased as per physician judgment. OBJECTIVE: To assess how the alirocumab dosing strategy was used by physicians during OLE. METHODS: Patients who entered OLE on a starting dose of alirocumab 75 mg every 2 weeks (Q2W) were included in the analysis (those from FH I, FH II, and LONG TERM trials)...
August 30, 2018: Journal of Clinical Lipidology
Piers Blackett, Minu George, Don P Wilson
Pediatric lipid screening and management with the aim of reducing and preventing adult disease is an internationally accepted concept, and guidelines have been published in several countries. However, implementation by the practicing pediatric community in the United States has been less than expected and delays have been attributed to uncertainty among providers. Reduced screening rates have also been reported for conditions contributing to arterial wall pathology such as obesity, hypertension, and prediabetes despite accumulating evidence that detection and intervention can lead to risk reversal...
August 29, 2018: Journal of Clinical Lipidology
Julian C van Capelleveen, Sang-Rok Lee, Rutger Verbeek, John J P Kastelein, Nicholas J Wareham, Erik S G Stroes, G Kees Hovingh, Kay-Tee Khaw, S Matthijs Boekholdt, Joseph L Witztum, Sotirios Tsimikas
BACKGROUND: Plasma apolipoprotein C-III (apoC-III) levels are associated with coronary artery disease (CAD) risk. OBJECTIVE: To assess whether lipoprotein-associated apoC-III levels predict risk of CAD events. METHODS: apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7...
August 29, 2018: Journal of Clinical Lipidology
Debi K Swertfeger, Sandra Rebholz, Hailong Li, Amy S Shah, William Sean Davidson, Long J Lu
BACKGROUND: Traditionally, the impact of lipoproteins on vascular disease has been evaluated in light of their quantity, that is, cholesterol content, in plasma. However, recent studies of high-density lipoproteins (HDLs) have focused on functionality with regard to atheroprotection. For example, bioassays have emerged to assess the ability of HDL, in its near native plasma environment, to promote cholesterol removal (efflux) from cells. As a result, attention has focused on developing plasma-based assays for other putative HDL protective functions including protecting low-density lipoproteins (LDLs) from oxidative damage...
August 27, 2018: Journal of Clinical Lipidology
Hayato Tada, Masa-Aki Kawashiri, Akihiro Nomura, Ryota Teramoto, Kazuyoshi Hosomichi, Atsushi Nohara, Akihiro Inazu, Hiroshi Mabuchi, Atsushi Tajima, Masakazu Yamagishi
BACKGROUND: The genetic background of severe familial hypercholesterolemia (FH) has yet to be determined. OBJECTIVE: We tested if genetic variants associated with low-density lipoprotein (LDL)-altering autosomal recessive diseases influenced LDL cholesterol levels and the odds for coronary artery disease in patients with high LDL cholesterol. METHODS: We recruited 500 individuals with elevated LDL cholesterol levels (≥180 mg/dL or ≥140 mg/dL for subjects <15 years)...
August 23, 2018: Journal of Clinical Lipidology
Allan D Sniderman, Matthew J McQueen
No abstract text is available yet for this article.
September 2018: Journal of Clinical Lipidology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"